IL17A and psoriasis: The severity of psoriatic inflammation indicated by the Psoriasis Area and Severity Index (PASI) was positively correlated with S100A7 expression in the epidermis, which was downregulated during biological treatment with adalimumab, etanercept, ustekinumab [45,46], or a neutralizing antibody against IL-17A [47].